EU/3/19/2160: Orphan designation for the treatment of epidermolysis bullosa

Allogeneic skin-derived ABCB5-positive mesenchymal stem cells

Table of contents

Overview

On 29 May 2019, orphan designation (EU/3/19/2160) was granted by the European Commission to RHEACELL GmbH & Co. KG, Germany, for allogeneic skin-derived ABCB5-positive mesenchymal stem cells (also known as allo-APZ2-EB) for the treatment of epidermolysis bullosa.

Key facts

Active substance
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells
Intended use
Treatment of epidermolysis bullosa
Orphan designation status
Positive
EU designation number
EU/3/19/2160
Date of designation
29/05/2019
Sponsor

RHEACELL GmbH & Co. KG
Im Neuenheimer Feld 517
69120 Heidelberg
Germany
Tel. +49 6221 718330
E-mail: office@rheacell.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating